Nutlin-3 reverses the epithelial-mesenchymal transition in gemcitabine-resistant hepatocellular carcinoma cells
Authors:
- 8 July 2016
- journal article
- research article
- Published by Spandidos Publications in Oncology Reports
- Vol. 36 (3) , 1325-1332
Abstract
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publicationsKeywords
This publication has 38 references indexed in Scilit:
- Regulatory networks defining EMT during cancer initiation and progressionNature Reviews Cancer, 2013
- MDM2, MDMX and p53 in oncogenesis and cancer therapyNature Reviews Cancer, 2013
- Notch Signaling Activated by Replication Stress–Induced Expression of Midkine Drives Epithelial–Mesenchymal Transition and Chemoresistance in Pancreatic CancerCancer Research, 2011
- MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitroJournal of Gastroenterology and Hepatology, 2011
- Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistanceDrug Resistance Updates, 2010
- Nutlin-3a Induces Cytoskeletal Rearrangement and Inhibits the Migration and Invasion Capacity of p53 Wild-Type Cancer CellsMolecular Cancer Therapeutics, 2010
- Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathwaysJournal of Cancer Research and Clinical Oncology, 2010
- Acquisition of Epithelial-Mesenchymal Transition Phenotype of Gemcitabine-Resistant Pancreatic Cancer Cells Is Linked with Activation of the Notch Signaling PathwayCancer Research, 2009
- Reversal of P-glycoprotein–Mediated Multidrug Resistance by the Murine Double Minute 2 Antagonist Nutlin-3Cancer Research, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008